Voyageur Pharmaceuticals Ltd. (VM.V)
CAD 0.11
(50.0%)
CAD 0.11
(50.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 727.87 Thousand CAD | 15.38% |
| 2022 | 630.82 Thousand CAD | -4.51% |
| 2021 | 660.63 Thousand CAD | -31.81% |
| 2020 | 968.84 Thousand CAD | 13.62% |
| 2019 | 852.69 Thousand CAD | 13.57% |
| 2018 | 750.78 Thousand CAD | -21.72% |
| 2017 | 959.12 Thousand CAD | 2368.08% |
| 2016 | 38.86 Thousand CAD | 318.67% |
| 2015 | 9282.00 CAD | -88.17% |
| 2014 | 78.44 Thousand CAD | 814.22% |
| 2013 | 8581.00 CAD | -63.44% |
| 2012 | 23.47 Thousand CAD | 10.68% |
| 2011 | 21.2 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.07 Million CAD | 9.42% |
| 2024 Q1 | 985.21 Thousand CAD | 35.35% |
| 2024 Q3 | 1.38 Million CAD | 28.91% |
| 2023 Q2 | 438.88 Thousand CAD | -17.82% |
| 2023 Q3 | 467.66 Thousand CAD | 6.56% |
| 2023 Q4 | 727.87 Thousand CAD | 55.64% |
| 2023 FY | 727.87 Thousand CAD | 15.38% |
| 2023 Q1 | 534.02 Thousand CAD | -15.35% |
| 2022 Q3 | 389.95 Thousand CAD | -60.13% |
| 2022 Q4 | 630.82 Thousand CAD | 61.77% |
| 2022 FY | 630.82 Thousand CAD | -4.51% |
| 2022 Q1 | 470.5 Thousand CAD | -28.78% |
| 2022 Q2 | 978.02 Thousand CAD | 107.87% |
| 2021 Q1 | 751.33 Thousand CAD | -22.45% |
| 2021 Q2 | 598.07 Thousand CAD | -20.4% |
| 2021 Q3 | 605.72 Thousand CAD | 1.28% |
| 2021 Q4 | 660.63 Thousand CAD | 9.07% |
| 2021 FY | 660.63 Thousand CAD | -31.81% |
| 2020 Q3 | 849.8 Thousand CAD | 8.1% |
| 2020 Q2 | 786.09 Thousand CAD | 35.64% |
| 2020 Q1 | 579.56 Thousand CAD | -32.03% |
| 2020 FY | 968.84 Thousand CAD | 13.62% |
| 2020 Q4 | 968.84 Thousand CAD | 14.01% |
| 2019 Q2 | 716.68 Thousand CAD | -9.23% |
| 2019 FY | 852.69 Thousand CAD | 13.57% |
| 2019 Q4 | 852.69 Thousand CAD | 19.14% |
| 2019 Q3 | 715.67 Thousand CAD | -0.14% |
| 2019 Q1 | 789.54 Thousand CAD | 5.16% |
| 2018 Q3 | 613.82 Thousand CAD | -33.97% |
| 2018 Q1 | 875.29 Thousand CAD | -8.74% |
| 2018 FY | 750.78 Thousand CAD | -21.72% |
| 2018 Q4 | 750.78 Thousand CAD | 22.31% |
| 2018 Q2 | 929.69 Thousand CAD | 6.21% |
| 2017 Q3 | 840.68 Thousand CAD | 36.76% |
| 2017 FY | 959.12 Thousand CAD | 2368.08% |
| 2017 Q4 | 959.12 Thousand CAD | 14.09% |
| 2017 Q1 | 644.77 Thousand CAD | 1559.17% |
| 2017 Q2 | 614.71 Thousand CAD | -4.66% |
| 2016 FY | 38.86 Thousand CAD | 318.67% |
| 2016 Q3 | 12.22 Thousand CAD | 17.54% |
| 2016 Q2 | 10.39 Thousand CAD | 22.42% |
| 2016 Q4 | 38.86 Thousand CAD | 217.99% |
| 2016 Q1 | 8493.00 CAD | -8.5% |
| 2015 Q4 | 9282.00 CAD | 802.04% |
| 2015 Q2 | 3016.00 CAD | -96.25% |
| 2015 Q1 | 80.41 Thousand CAD | 2.51% |
| 2015 FY | 9282.00 CAD | -88.17% |
| 2015 Q3 | 1029.00 CAD | -65.88% |
| 2014 Q4 | 78.44 Thousand CAD | 55.33% |
| 2014 Q1 | 8019.00 CAD | -6.55% |
| 2014 Q2 | 58.04 Thousand CAD | 623.88% |
| 2014 Q3 | 50.5 Thousand CAD | -13.0% |
| 2014 FY | 78.44 Thousand CAD | 814.22% |
| 2013 Q2 | 12.73 Thousand CAD | -45.53% |
| 2013 Q4 | 8581.00 CAD | 240.65% |
| 2013 FY | 8581.00 CAD | -63.44% |
| 2013 Q3 | 2519.00 CAD | -80.23% |
| 2013 Q1 | 23.38 Thousand CAD | -0.37% |
| 2012 FY | 23.47 Thousand CAD | 10.68% |
| 2012 Q2 | 700.00 CAD | 0.0% |
| 2012 Q4 | 23.47 Thousand CAD | 268.49% |
| 2012 Q3 | 6370.00 CAD | 810.0% |
| 2011 FY | 21.2 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 5.38 Million CAD | 86.471% |
| CanadaBis Capital Inc. | 15.61 Million CAD | 95.34% |
| Decibel Cannabis Company Inc. | 96.79 Million CAD | 99.248% |
| Delivra Health Brands Inc. | 4.85 Million CAD | 85.017% |
| Entourage Health Corp. | 178.68 Million CAD | 99.593% |
| Lifeist Wellness Inc. | 9.94 Million CAD | 92.678% |
| Cannara Biotech Inc. | 61.77 Million CAD | 98.822% |
| Medicure Inc. | 8.16 Million CAD | 91.083% |
| PharmaCielo Ltd. | 23.96 Million CAD | 96.963% |
| Rubicon Organics Inc. | 16.99 Million CAD | 95.718% |
| BioSyent Inc. | 6.76 Million CAD | 89.247% |